

**South Dakota Department of Social Services, Division of Medicaid Services
Pharmacy & Therapeutics (P&T) Committee Meeting Minutes**

Friday, March 5, 2021

1:00 – 3:00 pm CT

Members and DSS Staff

Michelle Baack, MD	X	Heather Preuss, MD	X
Dana Darger, RPh, Chair	X	Matthew Stanley, DO	
Mikal Holland, MD		Deidre Van Gilder, PharmD	X
Bill Ladwig, RPh	X	Mike Jockheck, DSS Staff	X
Kelley Oehlke, PharmD	X	Matthew Ballard	X
Lenny Petrik, PharmD	X	Bill Snyder, DSS Staff	X

Administrative Business

Darger called the meeting to order at 1:03 pm. The minutes of the December meeting were presented. Baack made a motion to approve. Oehlke seconded the motion. The motion was unanimously approved via roll call vote.

Prior Authorization Update (PA) and Statistics

The committee reviewed the PA activity report from October 1, 2020 to December 31, 2020. A total of 1,494 PAs were reviewed of which 142 requests (9.5%) were received via telephone and 872 requests (58.4%) were received via fax, and 480 (32.1%) were reviewed via electronically. There was a 21.4% decrease of PAs received from the previous quarter.

Analysis of the Top 15 Therapeutic Classes and Drug Spend

The committee reviewed the top 15 therapeutic classes by total cost of claims from October 1, 2020 to December 31, 2020. The top five therapeutic classes based on paid amount were atypical antipsychotics, cystic fibrosis correctors, disease-modifying anti-rheumatic agents, amphetamines, and hemostatics. The top 15 therapeutic classes make up 25.39% of total claims. The committee also reviewed the top 50 drugs based on amount paid and number of claims. The top 50 drugs by amount paid make up 9.91% of total claims. New utilization for Evrysdi was noted on the top 50 drugs based on amount paid. Committee requested an asterisk notation if new drugs debut on the list or if a drug moves up the list by at least 10 spots.

Old Business

90-Day Fill

Jockheck provided an update on the 90-day fill which was implemented on 10/1/2020. A 90-day supply of generic maintenance medication is allowed after member establishes three monthly fills. There has been a slight uptick in utilization, about 600 per month. Provider notification was sent out to providers in February. A follow-up notice will be sent out to remind providers again.

Accumulation edit

Jockheck provided an update on the accumulation edit. The edit is not currently configured for the accumulation messaging. The edit would need to be configured before further consideration.

Atypical antipsychotic utilization in children

Committee reviewed atypical antipsychotic utilization in children 17 years old and under. Members currently taking 2 or more antipsychotics were specifically reviewed. Committee reviewed the proposed PA criteria for prescribers wanting to add a 3 or more atypical antipsychotics. Committee requested the criteria to be discussed at next meeting. Darger inquired if there was any public comment. There were none.

ADHD utilization

Committee reviewed ADHD utilization in members 21 years and older. They also reviewed the comparison of PMPM and PUPM of other state Medicaid. Baack and Preuss discussed diversion concerns. Committee requested utilization and PMPM/PUPM figures to be reviewed again at the next meeting.

Evrysdi

Committee reviewed utilization and proposed PA criteria for Evrysdi. Jeremy Whalen from Genentech provided public comment on Evrysdi. Baack requested to review the reauthorization criteria again in 12 months. Baack made a motion to approve the Evrysdi PA criteria with the following addendum – #7 The following exam has been conducted to establish baseline motor ability by a board-certified neurologist. Ladwig seconded the motion. The motion was unanimously approved via roll call vote.

Opioid update

The committee reviewed 4Q20 opioid outcomes compared to previous quarters from the opioid initiatives. There was a decrease in opioid utilization and opioid utilizers during fourth quarter even though there is an increase in eligible members. There was a 20% increase in medication assisted therapy during fourth quarter.

New Business

Antihistamine PA approval review

Committee reviewed the PA approval rate for antihistamines. Based on current trend, no changes were needed as the Committee deemed the reviews appropriate.

Analgesic/Anti-inflammatory PA approval review

Committee reviewed the PA approval rate for analgesics/anti-inflammatories. After review, Ladwig made a motion to remove quantity level limits on meloxicam. Baack seconded the motion Darger inquired if there was any public comment. There were none. The motion was unanimously approved via roll call vote.

Antidepressants PA approval rate

Committee reviewed the PA approval rate for antidepressants. Preuss pinpointed the large number of reviews for duloxetine 60mg. Due to the use of fibromyalgia and chronic pain, it's a better drug choice than opioids. Baack made a motion to increase the quantity level limit for duloxetine 60mg to 2 per day, 30mg, to 3 per day, and 20mg to 3 per day. Ladwig seconded the motion. Darger inquired if there was any public comment. There were none. The motion was unanimously approved via roll call vote. Ladwig suggested updating the quantity level limits to maximum dosage for each drug. Ladwig made a motion and Van Gilder seconded the motion. Darger inquired if there was any public comment. There were none. The motion was unanimously approved via roll call vote.

Relexxi

Relexxi was reviewed. More drugs to treat ADHD were approved recently. Committee requested to bring back new drugs and to continue the discussion to manage these class of drugs at the next meeting.

Adjournment

The next meeting is scheduled for June 11, 2021. The September meeting is tentatively scheduled on September 17, 2021. Ladwig made a motion to adjourn the meeting and Baack seconded the motion. The motion passed unanimously, and the meeting adjourned at 2:50 PM.

DRAFT